Sarepta price target raised to $185 from $141 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on Sarepta Therapeutics to $185 from $141 and keeps an Overweight rating on the shares. The company’s Q4 highlighted the acceptance of Elevidys supplemental application, with an on-track FDA action date and disclosed SRP-9003 pivotal trial development path, the analyst tells investors in a research note. The firm continues to expect a broad label and strong launch for Elevidys.